AG真人官方

Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance

贬颈驳丑濒颈驳丑迟蝉鈥�

• Reported revenue of $382.5 million, up 13.2%
• Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectively
• GAAP operating margin of 12.3%, compared to 13.6% in prior year period
• Non-GAAP operating margin* of 21.2%, compared to 20.1% in prior year period
• GAAP EPS $0.54, down 11.6%
• Non-GAAP EPS* $1.01, up 9.8%
• Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-year
• Acquired Biolife Delaware, L.L.C. (鈥淏iolife鈥�), a manufacturer of hemostatic devices branded as StatSeal^庐 and WoundSeal^庐
• Martha Aronson named as new President and Chief Executive Officer, effective October 3, 2025
  

鈥� Comparisons above are calculated for the current quarter compared with the second quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

*听Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading 鈥淣on-GAAP Financial Measures鈥� below.

SOUTH JORDAN, Utah, July 30, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced revenue of $382.5 million for the quarter ended June听30,听2025, an increase of 13.2% compared to the quarter ended June听30,听2024. Constant currency revenue for the second quarter of 2025 increased 12.5% compared to the prior year period and constant currency revenue, organic, for the second quarter of 2025 increased 6.7% compared to the prior year period.

鈥淲e delivered better-than-expected financial performance in the second quarter, with our top-and-bottom line results exceeding the high-end of our forecast,鈥� said Fred P. Lampropoulos, Merit鈥檚 Chairman and Chief Executive Officer. 鈥淲e have increased our 2025 revenue and non-GAAP earnings per share guidance to reflect our stronger-than-expected first half financial results and our updated profitability expectations for the balance of the year. Specifically, we believe we can deliver higher non-GAAP gross and non-GAAP operating margins on a year-over-year basis in 2025, largely due to our currently projected impact of implemented trade policies and related actions by the U.S. and other countries since our first quarter report.鈥�

Mr. Lampropoulos continued: 鈥淲e are proud of the strong financial results over the first half of the year where we delivered constant currency, organic, growth of more than 6%, non-GAAP EPS growth of 12% and we generated more than $89 million of free cash flow. Our updated guidance reflects continued confidence in our team鈥檚 ability to deliver strong execution, stable constant currency growth, improving profitability and solid cash flow generation this year.鈥�

Merit鈥檚 revenue by operating segment and product category for the three and six-month periods ended June听30,听2025 and 2024 was as follows (unaudited; in thousands, except for听percentages):

Merit鈥檚 GAAP gross margin for the second quarter of 2025 was 48.2%, compared to GAAP gross margin of 47.7% for the second quarter of 2024. Merit鈥檚 non-GAAP gross margin* for the second quarter of 2025 was 53.2%, compared to non-GAAP gross margin* of 51.5% for the second quarter of 2024.

Merit鈥檚 GAAP net income for the second quarter of 2025 was $32.6 million, or $0.54 per share, compared to GAAP net income of $35.7 million, or $0.61 per share, for the second quarter of 2024. Merit鈥檚 non-GAAP net income* for the second quarter of 2025 was $61.0 million, or $1.01 per share, compared to non-GAAP net income* of $53.8 million, or $0.92 per share, for the second quarter of 2024.

As of June听30,听2025, Merit had cash and cash equivalents of $341.8 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $376.7 million and total debt obligations of $747.5 million as of December听31,听2024. Merit had available borrowing capacity of approximately $697 million as of June听30,听2025.

Fiscal Year 2025 Financial Guidance

Based upon the information currently available to Merit鈥檚 management, for the year ending December 31, 2025, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today鈥檚 date, material acquisitions, non-recurring transactions or other factors beyond Merit鈥檚 current expectations, Merit anticipates the following financial results:

Revenue and Earnings Guidance*

*Percentage figures approximated; dollar figures may not foot due to rounding
(1) Merit鈥檚 non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the 鈥淐onvertible Notes鈥�) calculated using the if-converted method of approximately $0.05 per share for the year ending December 31, 2025. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.
(2) 鈥淧rior Guidance鈥� reflects Merit鈥檚 full-year 2025 financial guidance, previously introduced on May 20, 2025.

2025 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*

*Percentage figures approximated and may not foot due to rounding
(1)鈥淧rior Guidance鈥� reflects Merit鈥檚 full-year 2025 financial guidance, previously introduced on May 20, 2025.

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit鈥檚 future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit鈥檚 financial guidance for the听year ending December听31, 2025 is subject to risks and uncertainties identified in this release and Merit鈥檚 filings with the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�). This guidance is based on information and estimates available to Merit as of July 30, 2025. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.

CONFERENCE CALL

Merit will hold its investor conference call today, Wednesday, July 30, 2025, at 5:00听p.m., Eastern Time. To access the conference call, please pre-register using the following . Registrants will receive confirmation with dial-in details. A live webcast and slide deck will also be available at merit.com.

Non-GAAP Financial Measures

Although Merit鈥檚 financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (鈥淕AAP鈥�), Merit鈥檚 management believes that the non-GAAP financial measures referenced in this release may provide investors with useful information regarding the underlying business trends and performance of Merit鈥檚 ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures used in this release include:

• constant currency revenue;
• constant currency revenue, organic;
• non-GAAP gross profit and margin;
• non-GAAP operating income and margin;
• non-GAAP net income;
• non-GAAP earnings per share; and
• free cash flow.
  

Merit鈥檚 management team uses these non-GAAP financial measures to evaluate Merit鈥檚 profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit鈥檚 management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.

Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit鈥檚 net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit鈥檚 business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit鈥檚 business or results of operations.

Constant Currency Revenue

Merit鈥檚 constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustments of ($2.3) million and $1.1 million to reported revenue for the three and six-month periods ended June听30,听2025, respectively, were calculated using the applicable average foreign exchange rates for the three and six-month periods ended June听30,听2024.

Constant Currency Revenue, Organic

Merit鈥檚 constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue. With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions. For the three and six-month periods ended June 30, 2025, Merit鈥檚 constant currency revenue, organic, excludes revenues attributable to (i) the acquisition of Biolife in May 2025, (ii) the assets acquired from Cook Medical Holdings, LLC (鈥淐ook Medical鈥�) in November 2024 and (iii) the assets acquired from EndoGastric Solutions, Inc. in July 2024.

Non-GAAP Gross Profit and Margin

Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.

Non-GAAP Operating Income and Margin

Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit鈥檚 management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, and other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliations

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit鈥檚 corresponding financial measures prepared in accordance with GAAP, in each case, for the three and six-month periods ended June听30,听2025 and 2024. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of $5.0 million and $3.4 million for the three-month periods ended June听30,听2025 and 2024, respectively and $9.3 million and $6.5 million for the six-month periods ended June听30,听2025 and 2024, respectively.

Reconciliation of GAAP Net Income to Non-GAAP Net Income
(Unaudited, in thousands except per share amounts)

______________________________

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of GAAP Net Income to Non-GAAP Net Income
(Unaudited, in thousands except per share amounts)

______________________________

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of Reported Operating Income to Non-GAAP Operating Income
(Unaudited, in thousands except percentages)

______________________________

Note: Certain percentages may not sum to totals due to rounding.

(a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

(b) Includes employee termination benefits associated with activities related to corporate restructuring initiatives and costs to terminate certain distribution contracts from our Biolife acquisition.

(c) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation.

(d) Represents costs to comply with Merit鈥檚 corporate integrity agreement with the U.S. Department of Justice (the 鈥淒OJ鈥�).

Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP)
(Unaudited, in thousands except听percentages)

______________________________

(a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this release entitled 鈥淣on-GAAP Financial Measures.鈥�

Reconciliation of Reported Gross Margin to Non-GAAP Gross Margin (Non-GAAP)
(Unaudited, as a听percentage of reported revenue)

______________________________
Note: Certain percentages may not sum to totals due to rounding.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:

• statements proceeded or followed by, or that include the words, 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥渁nticipates,鈥� 鈥渋ntends,鈥� 鈥渟eeks,鈥� 鈥渂elieves,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渇orecasts,鈥� 鈥減otential,鈥� 鈥渢arget,鈥� 鈥渃ontinue,鈥� 鈥渦pcoming,鈥� 鈥渙ptimistic鈥� or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;
• statements that address Merit鈥檚 future operating performance or events or developments that Merit鈥檚 management expects or anticipates will occur, including, without limitation, any statements regarding Merit鈥檚 projected revenues, earnings or other financial measures, Merit鈥檚 plans and objectives for future operations, Merit鈥檚 proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit鈥檚 Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and
• statements regarding Merit鈥檚 past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.
  

The forward-looking statements contained in this release are based on Merit management鈥檚 current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and could differ materially, from Merit鈥檚 expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

The following are some of the important risks and uncertainties that could cause Merit鈥檚 actual results to differ from Merit鈥檚 expectations in any forward-looking statements: inherent risks and uncertainties associated with consequences of Merit鈥檚 executive succession planning activities and leadership transition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed or prospective tariffs, duties or other measures; inherent risks and uncertainties associated with Merit鈥檚 acquisition of Biolife in May 2025; Merit鈥檚 integration of the Biolife business and operations and its ability to achieve revenues and other financial measures consistent with its forecasts projected for the Biolife acquisition; inherent risks and uncertainties associated with Merit鈥檚 integration of the business and products acquired from Cook Medical in November 2024 and Merit鈥檚 ability to achieve anticipated financial results, product development and other anticipated benefits of such acquisition; effects of the Convertible Notes on Merit鈥檚 net income and earnings per share performance; disruptions in Merit鈥檚 supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit鈥檚 potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; fluctuations in interest or foreign currency exchange rates and inflation; risks and uncertainties associated with Merit鈥檚 information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit鈥檚 products; the safety, efficacy and patient and physician adoption of Merit鈥檚 products; uncertainties regarding enrollment and outcomes of ongoing and future clinical trials and market studies relating to Merit鈥檚 products; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit鈥檚 employees or agents violate the U.S Foreign Corrupt Practices Act or other laws or regulations; consequences associated with a Corporate Integrity Agreement executed between Merit and the DOJ; restrictions on Merit鈥檚 liquidity or business operations resulting from its debt agreements; infringement of Merit鈥檚 technology or the assertion that Merit鈥檚 technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit鈥檚 effective tax rate; termination of relationships with Merit鈥檚 suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit鈥檚 existing or future products obsolete; market acceptance of new products; dependence on distributors to commercialize Merit鈥檚 products in various jurisdictions outside the U.S.; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties which may affect Merit鈥檚 business, operations and financial condition, see Part I, Item 1A, 鈥淩isk Factors鈥� in Merit鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, Part II, Item 1A, 鈥淩isk Factors鈥� in Merit鈥檚 Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC and Merit鈥檚 other filings with the SEC.

All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc.,鈥痠ts subsidiaries, or its licensors.